Literature DB >> 25384896

Air sparging for prevention of antibody disulfide bond reduction in harvested CHO cell culture fluid.

Melissa Mun1, Stefanie Khoo, Aline Do Minh, James Dvornicky, Melody Trexler-Schmidt, Yung-Hsiang Kao, Michael W Laird.   

Abstract

During the scale-up of several Chinese Hamster Ovary (CHO) cell monoclonal antibody production processes, significant reduction of the antibody interchain disulfide bonds was observed. The reduction was correlated with excessive mechanical cell shear during the harvest operations. These antibody reduction events resulted in failed product specifications and the subsequent loss of the drug substance batches. Several methods were recently developed to prevent antibody reduction, including modifying the cell culture media, using pre- and post-harvest chemical additions to the cell culture fluid (CCF), lowering the pH, and air sparging of the harvested CCF (HCCF). The work described in this paper further explores the option of HCCF air sparging for preventing antibody reduction. Here, a small-scale model was developed using a 3-L bioreactor to mimic the conditions of a manufacturing-scale harvest vessel and was subsequently employed to evaluate several air sparging strategies. In addition, these studies enabled further understanding of the relationships between cell lysis levels, oxygen consumption, and antibody reduction. Finally, the effectiveness of air sparging for several CHO cell lines and the potential impact on product quality were assessed to demonstrate that air sparging is an effective method in preventing antibody reduction.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  air; antibody; dissolved oxygen; disulfide; lysis; reduction; sparging

Mesh:

Substances:

Year:  2014        PMID: 25384896     DOI: 10.1002/bit.25495

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  6 in total

1.  Using hydrogen peroxide to prevent antibody disulfide bond reduction during manufacturing process.

Authors:  Cheng Du; Yunping Huang; Ameya Borwankar; Zhijun Tan; Anthony Cura; Joon Chong Yee; Nripen Singh; Richard Ludwig; Michael Borys; Sanchayita Ghose; Nesredin Mussa; Zheng Jian Li
Journal:  MAbs       Date:  2018-01-23       Impact factor: 5.857

2.  Mechanistic insights into inter-chain disulfide bond reduction of IgG1 and IgG4 antibodies.

Authors:  Yuanli Song; Hui Cai; Zhijun Tan; Nesredin Mussa; Zheng-Jian Li
Journal:  Appl Microbiol Biotechnol       Date:  2022-01-24       Impact factor: 4.813

3.  Effects of antibody disulfide bond reduction on purification process performance and final drug substance stability.

Authors:  Wai Keen Chung; Brian Russell; Yanhong Yang; Michael Handlogten; Suzanne Hudak; Mingyan Cao; Jihong Wang; David Robbins; Sanjeev Ahuja; Min Zhu
Journal:  Biotechnol Bioeng       Date:  2017-03-06       Impact factor: 4.530

4.  Optimization and kinetic modeling of interchain disulfide bond reoxidation of monoclonal antibodies in bioprocesses.

Authors:  Peifeng Tang; Zhijun Tan; Vivekh Ehamparanathan; Tingwei Ren; Laurel Hoffman; Cheng Du; Yuanli Song; Li Tao; Angela Lewandowski; Sanchayita Ghose; Zheng Jian Li; Shijie Liu
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

5.  Untargeted proteomics reveals upregulation of stress response pathways during CHO-based monoclonal antibody manufacturing process leading to disulfide bond reduction.

Authors:  Seo-Young Park; Susan Egan; Anthony J Cura; Kathryn L Aron; Xuankuo Xu; Mengyuan Zheng; Michael Borys; Sanchayita Ghose; Zhengjian Li; Kyongbum Lee
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

6.  On-column disulfide bond formation of monoclonal antibodies during Protein A chromatography eliminates low molecular weight species and rescues reduced antibodies.

Authors:  Zhijun Tan; Vivekh Ehamparanathan; Tingwei Ren; Peifeng Tang; Laurel Hoffman; June Kuang; Peiran Liu; Chao Huang; Cheng Du; Li Tao; Letha Chemmalil; Angela Lewandowski; Sanchayita Ghose; Zheng Jian Li; Shijie Liu
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.